Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events

QR Code

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events

Toyoaki Tsumura,1 Keiji Yoshikawa,2 Hirotaka Suzumura,3 Tairo Kimura,4 Satoshi Sasaki,5 Itaru Kimura,6 Ryuji Takeda71Department of Ophthalmology, Fussa Hospital, Fussa, Tokyo, Japan; 2Yoshikawa Eye Clinic, Machida, Tokyo, Japan; 3Department of Ophthalmology, Nakano General Hospital, Nakano, Tokyo, J...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2012
Sujets:	Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/c2bd21ac85c54b78af74f98a1cee9154
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
par: Tsumura T, et autres
Publié: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
par: Tsumura T, et autres
Publié: (2013)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
par: Inoue K, et autres
Publié: (2014)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
par: Shafiee A, et autres
Publié: (2013)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study
par: Deshpande SS, et autres
Publié: (2017)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
par: Moataz E Gheith, et autres
Publié: (2008)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
par: Abayomi B Ogundele, et autres
Publié: (2010)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
par: Pfennigsdorf S, et autres
Publié: (2016)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
par: Pillunat LE, et autres
Publié: (2016)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
par: Chang-Lin J-E, et autres
Publié: (2011)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
par: Myers JS, et autres
Publié: (2014)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
par: Abayomi B Ogundele, et autres
Publié: (2010)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
par: Wirta D, et autres
Publié: (2011)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients
par: Tsumura T, et autres
Publié: (2014)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]
par: Tsumura T, et autres
Publié: (2015)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]
par: Tsumura T, et autres
Publié: (2015)

Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects
par: Mizoue S, et autres
Publié: (2014)

Relationship between progression of visual field defect and intraocular pressure in primary open-angle glaucoma
par: Naito T, et autres
Publié: (2015)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
par: Inoue K, et autres
Publié: (2012)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
par: Schnober D, et autres
Publié: (2015)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
par: Lee D, et autres
Publié: (2017)

Relationship between consecutive deterioration of mean deviation value and progression of visual field defect in open-angle glaucoma
par: Naito T, et autres
Publié: (2015)

Intraocular asymmetry of visual field defects in primary angle-closure glaucoma, high-tension glaucoma, and normal-tension glaucoma in a Chinese population
par: Junhong Jiang, et autres
Publié: (2021)

Si0.97Ge0.03 microelectronic thermoelectric generators with high power and voltage densities
par: Ruchika Dhawan, et autres
Publié: (2020)

Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma
par: Yuya Nomura, et autres
Publié: (2010)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
par: Andrea Russo, et autres
Publié: (2009)

Serum free fatty acids levels not associated with normal tension glaucoma
par: Kenya Yuki, et autres
Publié: (2010)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
par: Stevens A, et autres
Publié: (2016)

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
par: Hassan Sajjad Rathore, et autres
Publié: (2021)

Relationship between visual field progression and baseline refraction in primary open-angle glaucoma
par: Naito T, et autres
Publié: (2016)

Effect of quantitative intraocular pressure reduction on visual field defect progression in normal tension glaucoma under medical therapy applying Markov model
par: Yoshikawa K, et autres
Publié: (2018)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
par: Scott D Smid
Publié: (2009)

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
par: Takemoto D, et autres
Publié: (2017)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
par: Shen J, et autres
Publié: (2017)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
par: Mizoguchi T, et autres
Publié: (2011)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
par: Shen J, et autres
Publié: (2018)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
par: Shen J, et autres
Publié: (2016)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
par: Ikeda Y, et autres
Publié: (2016)

Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
par: Sheppard JD, et autres
Publié: (2019)

Lowered intraocular pressure in a glaucoma patient after intravitreal injection of ocriplasmin
par: McClintock M, et autres
Publié: (2015)